Ad A. van Bodegraven

P0027 The carbon footprint of remote monitoring of IBD patients – a green opportunity for sustainable outpatient care

Evelien M. B. Hendrix, D C de Jong, Marin J. de Jong, Marco C. Becx et autres

Abstract Background Climate change is a major public health threat, with healthcare systems contributing 4-5% of global greenhouse gas (GHG) emissions. Inflammatory Bowel Disease (IBD), a chronic and increasingly prevalent condition, demands extensive healthcare resources, making healthcare for this patient population a …

nl, aw (code pays fourni par la source)

Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease

Femke Crouwel, Melek Simsek, Marjon Alina de Boer, Chris J. Mulder et autres

BACKGROUND: Safety of thioguanine in pregnant patients with inflammatory bowel disease [IBD] is sparsely recorded. This study was aimed to document the safety of thioguanine during pregnancy and birth. METHODS: In this multicentre case series, IBD patients treated with thioguanine during pregnancy …

nl, ca (code pays fourni par la source)

Gene expression responses reflecting 5-FU-induced toxicity: Comparison between patient colon tissue and 3D human colon organoids

Daniela Rodrigues, Roel van Kampen, Ad A. van Bodegraven, Jos C. S. Kleinjans et autres

Capecitabine is a chemotherapeutic drug that is widely used as a monotherapy option in advanced cancer patients. After administration, it is converted into its active metabolite 5-fluorouracil (5-FU), a cytotoxic compound that may also induce adverse side effects in the gastrointestinal (GI) …

nl (code pays fourni par la source)

DOP75 Effectiveness and Safety of tofacitinib versus vedolizumab in Patients with Ulcerative Colitis; A Nationwide, ICC Registry study

Tessa Straatmijer, Marijn Caroline Visschedijk, Andrica de Vries, Frank Hoentjen et autres

Abstract Background Clinicians face difficulty in positioning biologics and JAK inhibitors in anti-TNF refractory ulcerative colitis (UC) patients. Head-to-head trials comparing the efficacy of vedolizumab and tofacitinib in UC patients are lacking. We aimed to compare the effectiveness and safety of vedolizumab …

nl, ca (code pays fourni par la source)

P687 Prevalence of iron deficiency and anaemia in the outpatient Inflammatory Bowel Disease population: a Dutch national cross-sectional study

Roberta Loveikyte, M. den Boer, Catharina N. van der Meulen, Rinze W. F. ter Steege et autres

Abstract Background Iron deficiency (ID) and anaemia in Inflammatory Bowel Disease (IBD) are associated with reduced quality of life, worse disease outcomes, and an increase in healthcare costs. In the European guidelines, anaemia is listed as one of the treatment goals. The …

nl, ca (code pays fourni par la source)

Severe COVID-19 in inflammatory bowel disease patients in a population-based setting

Rob H. Creemers, Ashkan Rezazadeh Ardabili, Daisy M.A.E. Jonkers, Mathie P.G. Leers et autres

OBJECTIVE: Data on the course of severe COVID-19 in inflammatory bowel disease (IBD) patients remains limited. We aimed to determine the incidence rate and clinical course of severe COVID-19 in the heavily affected South-Limburg region in the Netherlands. METHODS: All COVID-19 patients …

nl (code pays fourni par la source)

Feasibility and Efficiency of the BEFORE (Better Exercise and Food, Better Recovery) Prehabilitation Program

Thaís T. T. Tweed, Misha A. T. Sier, Ad A. van Bodegraven, Noémi C. van Nie et autres

Prehabilitation has been postulated as an effective preventive intervention to reduce postoperative complications, particularly for elderly patients with a relatively high risk of complications. To date, it remains to be determined whether prehabilitation increases physical capacity and reduces postoperative complications. The aim …

nl (code pays fourni par la source)

P637 Incidence rate and clinical outcome of severe COVID-19 in Inflammatory Bowel Disease patients in a population-based setting

Ashkan Rezazadeh Ardabili, Rob H. Creemers, Daisy M.A.E. Jonkers, Mariëlle J. L. Romberg-Camps et autres

Abstract Background The broad use of immunosuppressants and biologicals in Inflammatory Bowel Disease (IBD) patients increases the susceptibility to severe infections, and possibly COVID-19. Recently, in a Swedish population-based study it was suggested that IBD patients are at an increased risk of …

nl (code pays fourni par la source)

DOP54 Real-world effectiveness of thiopurine monotherapy in Crohn’s Disease: Is there still a place for thiopurines in the biological era?

Ashkan Rezazadeh Ardabili, Steven F. G. Jeuring, Zlatan Mujagic, Mariëlle J. L. Romberg-Camps et autres

Abstract Background In current guidelines, thiopurines are still recommended as first-line maintenance therapy for patients with Crohn’s disease (CD). Due to their lack of immunogenicity, oral administration route and low costs, thiopurines are an attractive first-line treatment option. However, in recent studies …

nl (code pays fourni par la source)

Poor nutritional status, risk of sarcopenia and nutrition related complaints are prevalent in COVID-19 patients during and after hospital admission

Nicolette Wierdsma, Hinke M. Kruizenga, Daphne Krebbers, Jolein RMC. Jorissen et autres

Background and aims Patients with COVID-19 infection presents with a broad clinical spectrum of symptoms and complications. As a consequence nutritional requirements are not met, resulting in weight- and muscle loss, and malnutrition. The aim of the present study is to delineate …

nl (code pays fourni par la source)

Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease

Shaden Mahmmod, Johannes P. D. Schultheiss, Ad A. van Bodegraven, Gerard D. H. Dijkstra et autres

BACKGROUND: Patients suffering from inflammatory bowel diseases (IBD) and treated with originator infliximab are increasingly being switched to biosimilars. Some patients, however, are "reverse switched" to treatment with the originator. Here we assess the prevalence of reverse switching, including its indication and …

nl (code pays fourni par la source)

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial

Toer W. Stevens, Maria L. Haasnoot, Geert D’Haens, Christianne Johanna Buskens et autres

nl (code pays fourni par la source)